Medico Remedies Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
MEDICO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medico Remedies has reported its unaudited standalone results for Q3 FY26 and the nine months ended December 31, 2025. Revenue from operations for Q3 FY26 came in at Rs 5,868 lakhs, up roughly 49% YoY from Rs 3,949 lakhs in Q3 FY25, while net profit rose about 10% YoY to Rs 287 lakhs from Rs 262 lakhs. For the nine-month period, revenue grew about 36% YoY to Rs 14,957 lakhs and PAT grew about 26% YoY to Rs 726 lakhs, translating to an EPS of Rs 0.87. The company continues to be export-heavy, with about Rs 5,156 lakhs of Q3 sales coming from outside India versus Rs 690 lakhs domestically. There has also been a change in statutory auditor mid-year — from M/s V J Shah & Co to Shah Shroff & Associates — and the new auditor issued an unmodified limited review report.
Strong top-line growth, especially from exports, is a positive signal, but Q3 profit growth of ~10% lagging revenue growth of ~49% suggests rising costs and margin pressure worth monitoring. The mid-year auditor change is a governance point shareholders should track.